Compare ZDGE & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | MIRA |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 44.0M |
| IPO Year | 2016 | 2023 |
| Metric | ZDGE | MIRA |
|---|---|---|
| Price | $3.01 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 65.8K | ★ 168.6K |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ 73.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $0.83 |
| 52 Week High | $4.70 | $2.45 |
| Indicator | ZDGE | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 45.07 |
| Support Level | $2.91 | $0.90 |
| Resistance Level | $3.19 | $1.24 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 56.82 | 40.58 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.